Objective To investigate the clinicopathological features, diagnosis, differential diagnosis and prognosis of intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC). Methods The clinicopathological data of 7 patients with intracranial SFT/HPC diagnosed in JiuJiang No.1 People's Hospital and Jiangxi Cancer Hospital from Jun. 2015 to Dec. 2020 were collected, and the histological morphology and immunohistochemistry results were analyzed retrospectively. Results Of the 7 cases of intracranial SFT/HPC, 5 were males and 2 were females, aged from 23 to 60 years, with a mean age of 46.1 years. The main clinical manifestations were dizziness, headache, vomiting and other symptoms of nerve compression and increased intracranial pressure. Imaging showed intracranial space occupying lesions with arterial phase enhancement. Microscopically, the tumors in 5 cases of World Health Organization (WHO) gradeⅡ SFT/HPC were composed of short spindle cells with interstitial "antler like" vascular and fibrous hyperplasia; the tumor cells in 2 cases of WHOⅢ SFT/HPC were significantly abundant and heterotypic. Immunohistochemical staining showed that vimentin, CD34, and signal transducer and activator of transcription 6 (STAT6) were diffusely expressed in tumor cells of 7 patients, and Bcl-2 (3/7), P53 (3/7) and CD99 (2/5) were expressed in varying degrees. Except for 1 patient transferred to other hospital and lost, the other 6 patients were followed up for 5 to 67 months. One patient recurred 33 months after the operation, and there was no recurrence or metastasis after the secondary operation. Conclusion Intracranial SFT/HPC is rare. With atypical clinical and imaging manifestations, it is easy to be confused with other intracranial tumors. The diagnosis depends on its characteristics of histological morphology and immunohistochemical markers. Early detection, complete surgical resection and radiotherapy can reduce recurrence of SFT/HPC.